Agios Pharmaceuticals Statistics
Share Statistics
Agios Pharmaceuticals has 57.03M shares outstanding. The number of shares has increased by 2.07% in one year.
| Shares Outstanding | 57.03M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.21% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 55.14M |
| Failed to Deliver (FTD) Shares | 280 |
| FTD / Avg. Volume | 0.04% |
Short Selling Information
The latest short interest is 4.34M, so 7.61% of the outstanding shares have been sold short.
| Short Interest | 4.34M |
| Short % of Shares Out | 7.61% |
| Short % of Float | 7.87% |
| Short Ratio (days to cover) | 9.39 |
Valuation Ratios
The PE ratio is -3.52 and the forward PE ratio is -9.71.
| PE Ratio | -3.52 |
| Forward PE | -9.71 |
| PS Ratio | 46.21 |
| Forward PS | 20.8 |
| PB Ratio | 1.53 |
| P/FCF Ratio | -4.17 |
| PEG Ratio | n/a |
Enterprise Valuation
Agios Pharmaceuticals Inc. has an Enterprise Value (EV) of 1.22B.
| EV / Earnings | -3.47 |
| EV / Sales | 45.6 |
| EV / EBITDA | -3.18 |
| EV / EBIT | -3.12 |
| EV / FCF | -4.12 |
Financial Position
The company has a current ratio of 12.27, with a Debt / Equity ratio of 0.09.
| Current Ratio | 12.27 |
| Quick Ratio | 11.99 |
| Debt / Equity | 0.09 |
| Total Debt / Capitalization | 8.15 |
| Cash Flow / Debt | -4.11 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.43% and return on capital (ROIC) is -44.34%.
| Return on Equity (ROE) | -0.43% |
| Return on Assets (ROA) | -0.38% |
| Return on Capital (ROIC) | -44.34% |
| Revenue Per Employee | 70.03K |
| Profits Per Employee | -919.29K |
| Employee Count | 383 |
| Asset Turnover | 0.03 |
| Inventory Turnover | 0.5 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 68.2% in the last 52 weeks. The beta is 0.75, so Agios Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 0.75 |
| 52-Week Price Change | 68.2% |
| 50-Day Moving Average | 49.71 |
| 200-Day Moving Average | 41.95 |
| Relative Strength Index (RSI) | 26.34 |
| Average Volume (20 Days) | 711.18K |
Income Statement
In the last 12 months, Agios Pharmaceuticals had revenue of $26.82M and earned -$352.09M in profits. Earnings per share was $-6.33.
| Revenue | 26.82M |
| Gross Profit | 17.32M |
| Operating Income | -391.49M |
| Net Income | -352.09M |
| EBITDA | -384.86M |
| EBIT | -391.49M |
| Earnings Per Share (EPS) | -6.33 |
Balance Sheet
The company has $88.20M in cash and $72.00M in debt, giving a net cash position of $16.21M.
| Cash & Cash Equivalents | 88.20M |
| Total Debt | 72.00M |
| Net Cash | 16.21M |
| Retained Earnings | -822.65M |
| Total Assets | 1.79B |
| Working Capital | 954.74M |
Cash Flow
In the last 12 months, operating cash flow was -$296.06M and capital expenditures -$999.00K, giving a free cash flow of -$297.06M.
| Operating Cash Flow | -296.06M |
| Capital Expenditures | -999.00K |
| Free Cash Flow | -297.06M |
| FCF Per Share | -5.34 |
Margins
Gross margin is 64.57%, with operating and profit margins of -1.46K% and -1.31K%.
| Gross Margin | 64.57% |
| Operating Margin | -1.46K% |
| Pretax Margin | -1.31K% |
| Profit Margin | -1.31K% |
| EBITDA Margin | -1.43K% |
| EBIT Margin | -1.46K% |
| FCF Margin | -1.11K% |
Dividends & Yields
AGIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -16.19% |
| FCF Yield | -13.33% |
Analyst Forecast
The average price target for AGIO is $54, which is 38.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $54 |
| Price Target Difference | 38.1% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
Scores
| Altman Z-Score | 8.85 |
| Piotroski F-Score | 4 |